UNSPSC 51142548: Budipine hydrochloride

This classification denotes an antiparkinson agent with the molecular formula C21H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NBF4Q9307Q, chemically known as 1-tert-butyl-4,4-diphenylpiperidine hydrochloride but more generally known as budipine hydrochloride, which bears US NIH Compound Identifier 3030419. European Medicines Agency schedules Budipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35026.

Most nations, for tariff and trade purposes, schedule budipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BUDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)N1CCC(CC1)(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51142548 Budipine hydrochloride is a Commodity code that nominally names a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code do not procure budipine itself. Instead, the code appears in opportunities for broader pharmaceutical procurement — naloxone, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local issuing bodies using this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves competitive bidding for pharmaceutical products with specific compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, FDA compliance, E-Verify workforce verification, and insurance coverage mandates. Contracts typically run two years with optional renewals, quarterly or ongoing delivery schedules, and fixed-fee or negotiated-net-price payment models.

Recent activity concentrates in the South and Upper Midwest. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to explore vendor capacity for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. MMCAP, administered by the Minnesota Department of Administration, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and maintain specific insurance and regulatory certifications. The code shows limited and somewhat mismatch activity — the nominal budipine ingredient does not appear in any recent opportunity, suggesting the code may be used as a catch-all pharmaceutical procurement category rather than for budipine-specific purchases.